Funding for this research was provided by:
deutsche forschungsgemeinschaft (814/2-1)
european union's horizon 2020 research and innovation program (667510)
Eberhard Karls Universität Tübingen
Received: 28 June 2021
Revised: 24 November 2021
Accepted: 26 November 2021
First Online: 10 December 2021
: BB is co-founder and share-holder of AIRAmed and has received consultancy fees from Medtronic (all outside of the submitted work); G.T. reports personal fees (advisory board, speaker`s fees) from AbbVie, Bayer, Bristol-Myers-Squibb, Medac, Novocure, travel grants from Bristol-Myers-Squibb, educational and travel grants from Novocure, research grants from Roche Diagnostics, research and travel grants from Medac; TL is co-founder, CEO and share-holder of AIRAmed, he has received travel grants from Bayer and presentation fees from Roche (all outside of the submitted work); XG is co-founder, CEO and share-holder of Gold Standard Phantoms; all other authors report no conflicts of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Tübingen (No. 374/2016BO1).
: Written informed consent was obtained from all individual participants included in the study.